Glioblastoma (GBM), is a highly aggressive and fast-growing disease; the most common and deadly primary brain cancer in adults. Standard treatments for the disease have not progressed or changed in over 30 years. But what if we were able to better predict a GBM patient’s likely response to a given therapy and improve prognosis?
Professor Andrew Scott AM, Laboratory Head of the Olivia Newton-John Cancer Research Institute and 2018 Innovation Grant recipient, reveals in his latest research update that the imaging technique to potentially achieve these improvements in therapy has been developed using FET-positron-emission tomography (FET-PET), in a clinical trial of 210 patients. The information from this study can be used to guide treatment regimens for GBM and hopes to promote personalised therapies to improve survival for those with brain cancer.
Professor Scott shares, “The grant from Cure Brain Cancer Foundation has enabled the development of the infrastructure for the collation and curation of the imaging data; the methodology for trial site image analysis credentialing and the purchase of software for the image analysis.” This Innovation Grant has enabled analysis of dynamic FET PET imaging, which may have improved potential for distinguishing between tumour and inflammatory change post-radiotherapy.
Unfortunately, the process for patient enrolment into this study was significantly delayed due to the COVID-19 pandemic. However, we are thrilled to report that patients have now been enrolled in 8 trial sites across Australia.
Lance Kawaguchi, Foundation CEO, congratulated Professor Scott, “It has been an incredibly challenging time for medical research throughout the pandemic, and we thank our dedicated researchers like Professor Scott, who persevered and are able to now report back to our community on the incredible work they are doing in brain cancer research. We look forward to seeing the outcomes of this study and are excited to see what it will mean for the future development of brain cancer therapy.”
In addition to the steps already achieved in this study, Professor Scott has stated that his team would like to next explore whether data gathered from MRI can provide prognostic information, as retrospective studies have previously suggested a possible link to treatment response. We look forward to keeping you updated on the progress of this research.
Read more on Professor Scott’s project here: https://www.curebraincancer.org.au/research/research-we-fund/imaging-and-molecular-determinants-of-response-to-chemoradiation-in-glioblastoma